# povetacicept

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/povetacicept
Canonical HTML page: https://getbiobrief.com/entity/povetacicept

## Timeline

- **2026-09-30**: Potential Approval — Estimated approval date based on 6-month priority review timeline.
- **2026-03-31**: FDA Filing Deadline — Target date for completing the BLA application for accelerated approval.
- **2026-03-09**: Phase 3 Success — Vertex announces povetacicept met primary endpoint in IgA nephropathy trial.
- **2024-04-10**: Alpine Acquisition — Vertex acquires Alpine Immune Sciences for $4.9B to obtain povetacicept.

## Recent coverage (1 stories)

### Vertex Kidney Drug Success Signals Major Pivot Beyond Cystic Fibrosis
2026-03-10 03:08:27 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Vertex Pharmaceuticals reported that its Phase 3 trial for povetacicept met its primary endpoint, showing a 52% reduction in proteinuria for patients with IgA nephropathy. The company plans to file for FDA accelerated approval by the end of March 2026, utilizing a priority review voucher to expedite the process.
Full story: https://getbiobrief.com/story/vertex-povetacicept-kidney-trial-success

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.